with a secondary analysis limited to AML and ALL patients receiving myeloablative conditioning extending from 1995 to 2009, prior to availability of novel antifungal agents, and the emergence of PBSC allografts. Patients with pre-transplant IFI were older, have lower performance status, have advanced disease, carry the diagnosis of AML, receive a cord blood transplant, receive RIT, receive mold-active fungal prophylaxis and be transplanted more recently. Aspergillus and Candidal infections were the most commonly identified pre-transplant IFI and 68% of patients presented with pulmonary involvement. Univariable outcomes analysis reveals lower 1-year, 3-year, and 5-year DFS and OS for patients with pre-transplant IFI (Table 1) . Relapses were higher in this cohort and there was a trend to increased TRM. The probability of post-transplant fungal infection was 24% for the study group and 17% for the control group (p <0.001). Interestingly, cause of death was associated with a greater likelihood of having recurrent/ persistent disease. Infectious mortality causes were only slightly increased (13 vs 9%) between the study group and the control group. With regard to the 2 o analysis comparing patients with pre-transplant IFI diagnosed between 1995 -2000 vs 2001-2009, TRM @ 1, 3, 5 yrs was significantly higher with associated reduction in OS and DFS for the early cohort. However, there were no observable differences in IFI post-transplant and in relapse rates. Conclusions: Documentation of pre-HSCT IFI is associated with lower DFS and OS after allogeneic HSCT. However, mortality is most influenced by patients with more advanced disease status than infectious etiologies. Treated pre-transplant IFI does not appear to be a contraindication to allogeneic HSCT.
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Human Herpesvirus-6 (HHV-6) Viremia Is Background: While CBT is a known risk factor for HHV-6 reactivation, the level of viremia associated with a high risk of HHV-6 encephalitis is not established and the association with CBT outcomes is controversial. Methods: We analyzed the nature of HHV-6 reactivation in 125 double-unit CB recipients who were transplanted for hematologic malignancies from 2/2006-3/2012. Viremia was measured by quantitative PCR of plasma HHV-6 DNA (lower detection limit 100 DNA copies/ml). Results: Of 125 patients (median age 42 years, range 1-69), 93 (74%) received myeloablative and 32 (26%) received non-myeloablative conditioning followed by 4-6/ 6 HLA-A,B antigen, -DRB1 allele matched CBT for the treatment of AML (n ¼ 43, 34%), ALL (n ¼ 24, 19%), MDS/ CML/ other leukemia (n ¼ 12, 10%), or lymphoma/ CLL (n ¼ 46, 37%). No patient received anti-thymocyte globulin (ATG). One-hundred and seventeen (94%) patients reactivated HHV-6 (median peak 7,600 copies/ml, range 100-160,000) at a median of 20 days (range 10-59). The median time to peak viremia was 23 days (range 12-62) and the median viremia duration was 8 days (range 1-60 days). Fifty-one patients (41% of total, 44% of viremic patients) developed HHV-6 > 10,000 copies/ml (median peak 31,200 copies/ml at 20 days, range 12-57). Only 6 patients (5% of total, 5% of viremic patients) had HHV-6 > 100,000 copies/ml (median peak 130,000 copies/ml at 19 days, range 14-29). HHV-6 encephalitis occurred in 2 patients (1.6%, peak viremias 13,000 and 118,000, respectively); 1 died from encephalitis and the other recovered with therapy. Four other viremic patients had HHV-6 isolated from bronchoalveolar lavage but did not meet criteria for HHV-6 pneumonia. Defining high level viremia as > 10,000 copies/ml in days 14-60, viremia was not associated with diagnosis or conditioning, engrafting unitrecipient HLA-match or TNC, CD34 þ , CD3 þ cell doses. Treating viremia as a time-dependent covariate in Cox regression analysis, no association was found between viremia and neutrophil or platelet engraftment. There was also no association between viremia and CMV reactivation, day 100 grade II-IV aGVHD, day 100 TRM, relapse, or overall survival. If high level viremia was defined as > 25,000 copies/ml (n ¼ 31, the highest peak viremia quartile days 14-60), no associations with CBT outcomes were detected. Finally, 24 patients had a second viremia (median onset day 49, range 100-27,300) without obvious sequelae. Conclusions: Nearly all our CBT recipients reactivate HHV-6. While the incidence of end-organ disease is low, possibly due to our exclusion of ATG from the conditioning, our understanding of the significance of HHV-6 viremia is incomplete. We are currently evaluating anti-viral treatment responses, and ultimately a prospective trial is needed to better define the causality between HHV-6 viremia and transplantation outcomes, and to investigate the risk-benefits of pre-emptive therapy. However, a recent multicenter randomized study failed to show survival benefit for AutoSCT perhaps due to high nonrelapse mortality (NRM). Here we present a comparison of AutoSCT to other conventional therapies in AL patients treated at our institution with a 14-year follow up. Methods: A total of 2018 cases were identified upon pathology review from 1998-2012. AL was confirmed in 264 patients; primary amyloidosis (PA) in 147 pts and multiple myeloma with amyloidosis (AM) in 110 patients; solitary amyloidoma in 7 patients. AutoSCT was performed in 126 patients (PA¼79 and AM¼47). Results: The day 100 NRM was 5% and 1-year NRM was 8%. With a follow up of 14 years in surviving patients, the 10-year overall survival (OS) of AL patients was significantly better in those undergoing AutoSCT (41% vs. 17%; p<0.0001; Figure 1 ). Involvement of more than one organ (6-yr OS 36% vs. 55%; p¼0.04) and cardiac involvement (2-yr OS of 57% vs. 78%; p¼0.01) were associated with poor outcome. In the patients undergoing AutoSCT: PA vs. AM, Mayo staging, Boston University (BU) staging or bone marrow plasma cells >10 % at the time of autoSCT did not have an impact on OS. Cardiac biomarkers including NT-ProBNP and Troponin-I and T levels were available in a limited number of patients and were not analyzed for survival outcomes. In multivariate analysis, superior OS was associated with: age <60yrs (HR 2.1, p¼0.022); and induction treatment before AutoSCT (HR 2.7, p¼0.02). Involvement of kidney as the only end organ showed a trend toward improved survival (HR 1.6, p¼0.06). Specifically for PA patients (n¼79); treatment before autoSCT was associated with improved 3yr OS: 85% vs. 66%; p¼0.02. 
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